# BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

> **NCT02052219** · PHASE3 · WITHDRAWN · sponsor: **Anthera Pharmaceuticals**

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** Blisibimod
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02052219
- **Lead sponsor:** Anthera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2016-10
- **Final completion:** 2021-10
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02052219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02052219, "BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02052219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*